- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Efficacy of Etanercept Treatment in Iraqi Patients with Moderate to Severe Psoriasis | ||
| Iraqi Postgraduate Medical Journal | ||
| Article 3, Volume 19, Issue 1, 2020, Pages 9-15 PDF (0 K) | ||
| Authors | ||
| Ihsan Al-Turfy1; Shahad Abdulmunaf Hamza2 | ||
| 1Department of Dermatology, College of Medicine, University of Baghdad | ||
| 2Center of Dermatology and Venereology, Medical City, Baghdad, Iraq | ||
| Abstract | ||
| ABSTRACT: BACKGROUND: Etanercept is a tumor necrosis factor (TNF) α inhibitor that has been approved for the treatment psoriasis. OBJECTIVE: Assessing the efficacy of etanercept therapy in Iraqi patients with moderate to severe psoriasis. PATIENTS AND METHODS: This study was a therapeutic interventional study at Medical City; center of dermatology and venereology (Baghdad, Iraq) from January 2017 till June 2018, with 53 patients, 31 (58.49%) males and 22 (41.51%) females, with 51 patients having moderate to severe plaque psoriasis and 2 patients with pustular psoriasis. All patients were given 50 mg subcutaneous injection of etanercept twice weekly for 3 months, followed by single injection of etanercept weekly for the next 9 months. Psoriasis area and severity index calculations were done every 3 months until 1year of treatment. RESULTS: The baseline PASI score changed from a mean ± standard deviation of 24.28 ± 14.56 to 1.62 ± 3.11 At the end of 12 months of treatment with a significant difference (P=0.001). Regarding the reduction in the patients' PASI score: At 3 months of treatment, (71.4%) achieved PASI 50, (48.2%) had PASI 75, and (5.35%) had PASI 90, at the 12th month of treatment (75.4%) reached PASI 90, (86.79%) reached PASI 75, &(94.33%) had PASI 50. Side effects were mild and tolerable. CONCLUSION: Etanercept is an effective therapy in treating moderate to severe psoriasis with tolerable side effects. | ||
| Keywords | ||
| psoriasis; etanercept; Tumor necrosis factor | ||
|
Statistics Article View: 1,170 PDF Download: 417 |
||